Premium
Milestones in umbilical cord blood transplantation
Author(s) -
Gluckman Eliane,
Ruggeri Annalisa,
Volt Fernanda,
Cunha Renato,
Boudjedir Karim,
Rocha Vanderson
Publication year - 2011
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2011.08598.x
Subject(s) - cord blood , umbilical cord , medicine , transplantation , stem cell , haematopoiesis , immunology , umbilical cord blood transplantation , hematopoietic stem cell transplantation , surgery , biology , genetics
Summary Much has been learned about umbilical cord blood (UCB) since the first human cord blood transplant was performed back in 1988. Cord blood banks have been established worldwide for the collection, cryopreservation and distribution of UCB for allogeneic haematopoietic stem cell transplantation. UCB has now become one of the most commonly used sources of haematopoietic stem cells for allogeneic transplantation. Today, a global network of cord blood banks and transplant centres has been established with a large common inventory, allowing for more than 20 000 transplants worldwide in children and adults with severe haematological diseases. Several studies have been published on UCB transplant, assessing risk factors such as cell dose and human leucocyte antigen mismatch. New strategies are ongoing to facilitate engraftment and reduce transplant‐related mortality and include the use of reduced‐intensity conditioning regimen, intra‐bone injection of cord blood cells, double cord blood transplants or ex vivo expansion of cord blood cells. The absence of ethical concern and the unlimited supply of cells explain the increasing interest of using UCB for developing regenerative medicine.